Group One Trading’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$757K Buy
274,200
+199,500
+267% +$496K ﹤0.01% 3036
2026
Q2
$174K Buy
74,700
+60,300
+419% +$128K ﹤0.01% 4395
2026
Q1
$31.2K Buy
+14,400
New +$35.7K ﹤0.01% 5627
2025
Q4
– Sell
-4,600
Closed -$10.2K – 8929
2025
Q3
$10.2K Buy
4,600
+4,300
+1,433% +$7K ﹤0.01% 7151
2025
Q2
$444 Sell
300
-1,100
-79% -$2.25K ﹤0.01% 7677
2025
Q1
$3.58K Sell
1,400
-600
-30% -$1.43K ﹤0.01% 6783
2024
Q4
$3.76K Buy
+2,000
New +$2.83K ﹤0.01% 6531
2024
Q3
– Sell
-3,400
Closed -$3.98K – 7203
2024
Q2
$3.98K Sell
3,400
-2,100
-38% -$2.48K ﹤0.01% 6042
2024
Q1
$6.93K Sell
5,500
-265,400
-98% -$396K ﹤0.01% 6050
2023
Q4
$482K Sell
270,900
-209,100
-44% -$325K ﹤0.01% 3104
2023
Q3
$797K Sell
480,000
-192,600
-29% -$346K ﹤0.01% 2486
2023
Q2
$1.35M Buy
672,600
+69,700
+12% +$166K ﹤0.01% 2074
2023
Q1
$1.27M Buy
602,900
+325,600
+117% +$571K ﹤0.01% 1936
2022
Q4
$380K Sell
277,300
-76,000
-22% -$83.4K ﹤0.01% 3297
2022
Q3
$368K Sell
353,300
-281,300
-44% -$312K ﹤0.01% 3533
2022
Q2
$692K Buy
634,600
+468,600
+282% +$548K ﹤0.01% 3122
2022
Q1
$176K Buy
166,000
+155,200
+1,437% +$142K ﹤0.01% 4931
2021
Q4
$9K Sell
10,800
-218,700
-95% -$229K ﹤0.01% 7411
2021
Q3
$305K Sell
229,500
-99,300
-30% -$151K ﹤0.01% 4731
2021
Q2
$628K Buy
328,800
+266,500
+428% +$917K ﹤0.01% 3965
2021
Q1
$278K Buy
62,300
+46,600
+297% +$217K ﹤0.01% 4664
2020
Q4
$57K Sell
15,700
-62,600
-80% -$224K ﹤0.01% 4931
2020
Q3
$303K Buy
78,300
+1,200
+2% +$4.34K ﹤0.01% 3313
2020
Q2
$292K Buy
+77,100
New +$264K ﹤0.01% 3072
2018
Q3
– Sell
-3,820
Closed -$16K – 5526
2018
Q2
$16K Sell
3,820
-30
-0.8% -$133 ﹤0.01% 4459
2018
Q1
$21K Sell
3,850
-8,960
-70% -$58.9K ﹤0.01% 4071
2017
Q4
$85K Buy
+12,810
New +$86.4K ﹤0.01% 3446
2017
Q3
– Sell
-7,750
Closed -$65K – 5079
2017
Q2
$65K Buy
7,750
+2,750
+55% +$25.8K ﹤0.01% 3366
2017
Q1
$68K Buy
+5,000
New +$45K ﹤0.01% 3218
2015
Q4
– Sell
-1,000
Closed -$12K – 5011
2015
Q3
$12K Sell
1,000
-5,230
-84% -$83.1K ﹤0.01% 4233
2015
Q2
$121K Buy
6,230
+3,960
+174% +$82.2K ﹤0.01% 2930
2015
Q1
$40K Buy
+2,270
New +$44.4K ﹤0.01% 3491
2014
Q4
– Sell
-80
Closed -$2K – 5192
2014
Q3
$2K Sell
80
-130
-62% -$3.74K ﹤0.01% 4935
2014
Q2
$8K Buy
+210
New +$8.47K ﹤0.01% 4600
2013
Q3
– Sell
-710
Closed -$35K – 5504
2013
Q2
$35K Buy
+710
New +$37.7K ﹤0.01% 3725

Other funds holding PLX

Group One Trading's PLX Position: Q3 2026 in Review

Group One Trading sold out of Protalix BioTherapeutics (PLX) in Q3 2026, closing a stake of 7,872 shares — an estimated $19.6K sold.

Group One Trading first reported a position in PLX in Q2 2013 and held it in 27 quarters. The position peaked at $551K in Q2 2014. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Group One Trading reported no remaining Protalix BioTherapeutics position as of Q3 2026 after selling out during the quarter.
  • Group One Trading sold 7,872 Protalix BioTherapeutics shares in Q3 2026, an estimated $19.6K.
  • Group One Trading first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 27 quarters.
  • Group One Trading's Protalix BioTherapeutics position peaked at $551K in Q2 2014.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.